Chemical Genetics of Plasmodium Kinases
Chemical Genetics of Plasmodium Kinases
批准号:
7880575
负责人:
DEBOPAM CHAKRABARTI
金额:
$35.26万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-07-01 至 2013-06-30
关键词:
AddressAffectAllelesAreaBindingBinding SitesCDC2 Protein KinaseCatalytic DomainCell CycleCell Cycle RegulationCell ExtractsCellsCharacteristicsCyclin-Dependent KinasesCytokinesisDNADNA biosynthesisDataDevelopmentDiseaseDrug Delivery SystemsDrug DesignDrug resistanceElectrostaticsEngineeringEnvironmentEnzymesErythrocytesEukaryotaEukaryotic CellExhibitsFamilyGene ExpressionGene Expression Microarray AnalysisGene TargetingGenerationsGlobal ChangeGoalsGrowthHaploidyHomologous GeneHot SpotHydrogen BondingKnock-outKnowledgeLabelLife Cycle StagesMalariaMicroarray AnalysisMicroscopicMissionMolecularOutcomeParasitesPathway interactionsPharmaceutical PreparationsPhenotypePhosphotransferasesPhysiologicalPlasmodiumPlasmodium falciparumPreparationPrevalencePropertyProteinsPublic HealthResearchResearch PersonnelRoleRouteScreening procedureShapesSignal PathwaySignal TransductionSiteSolutionsSpecificitySubstrate InteractionTechniquesTherapeuticTwo-Dimensional Gel ElectrophoresisWorkanalogasexualbasecell growthcellular targetingchemical geneticscombatdrug developmentexperienceglobal healthhuman diseasein vivoinhibitor/antagonistinnovationkillingsloss of functionmutantnovelnovel strategiesnovel therapeuticsprotein protein interactionpublic health relevanceresistant straintherapeutic target
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Malaria continues to be a global health problem killing 1-2 million people each year. Because of prevalence drug resistance it is urgent to identify new therapeutics for treatment. However, the development of new drugs by traditional screening approaches has lagged behind the required number of molecular entities to combat the disease and the serious problem of drug resistance. Additionally, there are only a few validated drug targets. This underscores the need for novel approaches to identify targets for drug development. Similar to all eukaryotes, cyclin-dependent kinases (CDKs) are likely to be key regulators of the novel intraerythrocytic cell cycle of the malaria parasite, where DNA replicates more than once per cell cycle without cytokinesis. Although several homologues of CDK-like kinases have been identified in P. falciparum, there is a fundamental gap in understanding about their physiological function. The long-term goal is to develop novel malaria therapeutics targeting Plasmodium CDK-like kinases. The objective of this application is to elucidate PfPK5, an essential closest Plasmodium homologue of metazoan CDK1, substrates through loss-of-function studies using chemical genetic approach. The chemical genetic approach will specifically label substrates of a given kinase using ATP analogs. The rationale for these proposed studies is that once PfPK5 physiological substrates are identified, it is expected that PfPK5- specific sites of protein-protein interactions will be exploited to develop mechanism-based route of interfering with PfPK5 function or the pathway where PfPK5 belongs. Thus, the proposed research is relevant to NIH's mission that pertains to developing fundamental knowledge that will potentially help to reduce the burden of human disease. Guided by strong preliminary data two specific aims will be pursued: (1) Identify P. falciparum proteins that are directly phosphorylated by PfPK5 by generating mutant kinases that are specifically able to utilize ATP analogs compared to the wild type kinases. Phosphorylated proteins will be identified by two-dimensional gel electrophoresis followed by mass spectrometric analysis. Candidate PfPK5 substrates will be validated. (2) Analyze phenotypic changes following loss of PfPK5 function by selective in vivo inhibition with ATP analogs. Global changes in gene expression will be analyzed by microarray analysis and phenotypic changes by microscopic and flow cytometric analysis following specific inhibition in PfPK5 activity. The proposed research is significant, because it will fundamentally advance our understanding of the molecular mechanisms of PfPK5 function in regulating Plasmodium falciparum intraerythrocytic life cycle. PUBLIC HEALTH RELEVANCE The proposed studies are of an important and under-investigated area of cell cycle regulation and signaling in Plasmodium falciparum. The proposed research has relevance to public health, because it will increase our understanding of the function of CDK-like kinases in Plasmodium falciparum that will aid in identifying parasite-specific signaling pathways and novel drug targets.
期刊论文(6)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1016/j.molbiopara.2009.01.003
发表时间:
2009-05
期刊:
MOLECULAR AND BIOCHEMICAL PARASITOLOGY
影响因子:
1.5
作者:
[Koyama, Fernanda C., Chakrabarti, Debopam, Garcia, Celia R. S.]
通讯作者:
Garcia, Celia R. S.
DOI:
10.3390/ijms151222320
发表时间:
2014-12-03
期刊:
International journal of molecular sciences
影响因子:
5.6
作者:
[Koyama FC, Azevedo MF, Budu A, Chakrabarti D, Garcia CR]
通讯作者:
Garcia CR
DOI:
10.1099/mic.0.049023-0
发表时间:
2011-10
期刊:
Microbiology (Reading, England)
影响因子:
--
作者:
[Dorin-Semblat D, Schmitt S, Semblat JP, Sicard A, Reininger L, Goldring D, Patterson S, Quashie N, Chakrabarti D, Meijer L, Doerig C]
通讯作者:
Doerig C
Plasmodium Protein Kinase Focused Antimalarials Discovery
-
批准号:10533634
-
项目类别:
-
资助金额:$80.13万
-
财政年份:2022
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Plasmodium Protein Kinase Focused Antimalarials Discovery
-
批准号:10663334
-
项目类别:
-
资助金额:$76.9万
-
财政年份:2022
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Novel Antimalarials from Fungi
-
批准号:10614534
-
项目类别:
-
资助金额:$75.59万
-
财政年份:2020
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Novel Antimalarials from Fungi
-
批准号:10166769
-
项目类别:
-
资助金额:$75.82万
-
财政年份:2020
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Novel Antimalarials from Fungi
-
批准号:10388240
-
项目类别:
-
资助金额:$75.69万
-
财政年份:2020
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Discovery of Antimalarials with Novel Mechanism of Action
-
批准号:10320854
-
项目类别:
-
资助金额:$37.04万
-
财政年份:2018
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Natural Product-Inspired Novel Synthetic Antiplasmodial Scaffolds
-
批准号:8872417
-
项目类别:
-
资助金额:$7.22万
-
财政年份:2015
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Novel Antimalarials from Marine Microbial Natural Products
-
批准号:8302637
-
项目类别:
-
资助金额:$22.84万
-
财政年份:2012
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Novel Antimalarials from Marine Microbial Natural Products
-
批准号:8424201
-
项目类别:
-
资助金额:$18.09万
-
财政年份:2012
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Chemical Genetics of Plasmodium Kinases
-
批准号:7879102
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2009
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Marine Natural Products as Antimalarials
-
批准号:7589385
-
项目类别:
-
资助金额:$19.05万
-
财政年份:2009
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Marine Natural Products as Antimalarials
-
批准号:7762252
-
项目类别:
-
资助金额:$21.35万
-
财政年份:2009
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Chemical Genetics of Plasmodium Kinases
-
批准号:7922270
-
项目类别:
-
资助金额:$5.4万
-
财政年份:2009
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Marine Natural Products as Antimalarials
-
批准号:7879131
-
项目类别:
-
资助金额:$0.7万
-
财政年份:2009
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Chemical Genetics of Plasmodium Kinases
-
批准号:7528116
-
项目类别:
-
资助金额:$36.67万
-
财政年份:2008
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
Chemical Genetics of Plasmodium Kinases
-
批准号:7645600
-
项目类别:
-
资助金额:$35.62万
-
财政年份:2008
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
CELL CYCLE OF PLASMODIUM FALCIPARUM
-
批准号:6190139
-
项目类别:
-
资助金额:$24.94万
-
财政年份:2000
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
CELL CYCLE OF PLASMODIUM FALCIPARUM
-
批准号:6374601
-
项目类别:
-
资助金额:$24.94万
-
财政年份:2000
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
CELL CYCLE OF PLASMODIUM FALCIPARUM
-
批准号:6632420
-
项目类别:
-
资助金额:$24.94万
-
财政年份:2000
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
CELL CYCLE OF PLASMODIUM FALCIPARUM
-
批准号:6511501
-
项目类别:
-
资助金额:$24.94万
-
财政年份:2000
-
负责人:DEBOPAM CHAKRABARTI
-
依托单位:
海外基金